Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Adam Folta.
Journal of Cancer Research and Clinical Oncology | 2018
Martin Čulen; Zdenka Kosarova; Ivana Jeziskova; Adam Folta; Jana Chovancová; Tomáš Loja; Nikola Tom; Vojtech Bystry; Veronika Janečková; Dana Dvorakova; Jiri Mayer; Zdenek Racil
PurposeThis study aimed at analyzing the association of gene mutations and other acute myeloid leukemia (AML) characteristics with engraftment outcomes in immunodeficient mice and to select the engraftment outcomes that best reflect patient survival.MethodsMutations in 19 genes as well as leukemia- and patient-related characteristics were analyzed for a group of 47 de novo AML samples with respect to three engraftment outcomes: engraftment ability, engraftment intensity (percentage of hCD45+ cells) and engraftment latency. Leukemia-related characteristics were additionally analyzed in an extended group of 68 samples that included the 47 de novo samples, and additional 21 samples from refractory and relapsed cases. Engraftment outcomes were compared with overall and event-free survival of the patients.ResultsFor the 47 de novo samples, no single mutation influenced engraftment, whereas the NPM1mut/DNMT3Amut co-mutation was associated with higher engraftment ability. NPM1mut/FLT3-ITDneg had lower engraftment intensity. Among leukemia-related characteristics, a complex karyotype was associated with higher engraftment intensity. Among patient-related characteristics, higher cytogenetic risk was associated with higher engraftment intensity, and failure to achieve clinical remission was associated with shorter engraftment latency. In the extended group of 68 samples, white blood count was associated with higher engraftment ability, and the presence of a complex karyotype was associated with higher engraftment intensity. Association with patient overall survival was seen only for engraftment intensity.ConclusionsThe engraftment of AML was influenced by mutation-interactions and other AML characteristics, rather than by single mutated genes, and engraftment intensity best reflected clinical penetrance of AML.
Archive | 2017
Zdeňka Kosařová; Martin Čulen; Ivana Ježíšková; Adam Folta; Veronika Janečková; Jana Černá; Tomáš Loja; Nikola Tom; Lukáš Semerád; Zuzana Šustková; Dana Dvořáková; Jiří Mayer; Zdeněk Ráčil
Archive | 2017
Adam Folta; Ivana Ježíšková; Dana Dvořáková; Nikola Tom; Martin Čulen; Zdeňka Kosařová; Anna Ďuriníková; Petr Cetkovský; P. Jindra; Tomáš Szotkowski; Pavel Žák; Mayer; Ráčil
Archive | 2017
Zdeňka Kosařová; Martin Čulen; Ivana Ježíšková; Adam Folta; Jana Chovancová; Tomáš Loja; Nikola Tom; Lukáš Semerád; Zuzana Šustková; Dana Dvořáková; Zdeněk Ráčil
Archive | 2017
Adam Folta; Ivana Ježíšková; Dana Dvořáková; Nikola Tom; Martin Čulen; Zdeňka Kosařová; Anna Ďuriníková; Petr Cetkovský; P. Jindra; Tomáš Szotkowski; Pavel Žák; Zdeněk Ráčil
Archive | 2017
Zdeňka Kosařová; Martin Čulen; Ivana Ježíšková; Adam Folta; Jana Chovancová; Tomáš Loja; Nikola Tom; Dana Dvořáková; Zuzana Šustková; Lukáš Semerád; Zdeněk Ráčil
Archive | 2017
Anna Ďuriníková; Ivana Ježíšková; Adam Folta; Dana Dvořáková; Zdeňka Kosařová; Martin Čulen; Petr Cetkovský; Pavel Žák; Tomáš Szotkowski; P. Jindra; Zdeněk Ráčil
Archive | 2017
Zdeňka Kosařová; Martin Čulen; Ivana Ježíšková; Adam Folta; Jana Černá; Tomáš Loja; Nikola Tom; Dana Dvořáková; Zuzana Šustková; Lukáš Semerád; Zdeněk Ráčil
Archive | 2017
Martin Čulen; Zdeňka Kosařová; Ivana Ježíšková; Adam Folta; Dana Dvořáková; Lukáš Semerád; Zuzana Šustková; Zdeněk Ráčil
Archive | 2016
Adam Folta; Ivana Ježíšková; Dana Dvořáková; Nikola Tom; Lukáš Semerád; Zuzana Šustková; Martin Čulen; Zdeňka Kosařová; Pavel Žák; Tomáš Szotkowski; P. Jindra; Petr Cetkovský; Zdeněk Ráčil